Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures.~* To prevent pregnancy, female participants of childbearing potential and their male partners will be required to use pre-specified, highly effective methods of non-hormonal contraception. Male participants with female partners of childbearing potential will be required to use a condom.~* Body weight ≥35 kg.~* Sweat chloride value ≥60 mmol/L from test results obtained during screening.~* Subjects must have an eligible CFTR genotype:~  * Heterozygous for F508del and a minimal function (MF) mutation known or predicted not to be responsive to TEZ and/or IVA.~ * Homozygous for F508del~* Subjects must have an FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height at the Screening Visit~* Stable CF disease as judged by the investigator.~* Willing to remain on a stable CF medication regimen through the planned end of treatment or, if applicable, the Safety Follow up Visit.~Exclusion Criteria:~* History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.~* History of cirrhosis with portal hypertension.~* Risk factors for Torsade de Pointes~* History of hemolysis.~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.~* Clinically significant abnormal laboratory values at screening~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before the first dose of study drug.~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* An acute illness not related to CF within 14 days before the first dose of study drug~* A standard digital ECG demonstrating QTc \>450 msec at screening.~* History of solid organ or hematological transplantation.~* History or evidence of cataract or lens opacity determined to be clinically significant by the ophthalmologist or optometrist based on the ophthalmologic examination during the Screening Period.~* History of alcohol or drug abuse in the past year, including but not limited to, cannabis, cocaine, and opiates, as deemed by the investigator.~* Ongoing or prior participation in an investigational drug study, with certain exceptions. (e.g., ongoing participation in NCT02565914)~* Use of commercially available CFTR modulator (e.g., Kalydeco, Orkambi) within 14 days before screening (applies only to the Heterozygous F508del/MF cohorts; does not apply to the Homozygous F508del/F508del Cohort).~* Pregnant or nursing females: Females of childbearing potential must have a negative pregnancy test at screening and Day 1.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Placebo - Cohort 1A and 1B Combined (Type: PLACEBO_COMPARATOR): Participants received placebo matched to VX-440/TEZ/IVA as triple combination for 4 weeks.
- Part 1 Cohort 1A: Triple Combination (TC) (Type: EXPERIMENTAL): Participants received VX-440 200 milligram (mg) every 12 hours (q12h)/TEZ 100 mg once daily (qd)/IVA 150 mg q12h as triple combination for 4 weeks.
- Part 1 Cohort 1B: TC Low Dose (Type: EXPERIMENTAL): Participants received VX-440 200 mg q12h/TEZ 50 mg q12h/IVA 150 mg q12h as triple combination for 4 weeks.
- Part 1 Cohort 1B: TC High Dose (Type: EXPERIMENTAL): Participants received VX-440 600 mg q12h/TEZ 50 mg q12h/IVA 300 mg q12h as triple combination for 4 weeks.
- Part 2: TEZ/IVA (Type: ACTIVE_COMPARATOR): Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received placebo matched to VX-440 and TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
- Part 2: TC-2 (Type: EXPERIMENTAL): Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received VX-440 600 mg q12h/ TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.

Based on this trial design, predict the completion outcome and termination type (if applicable).